# US 2026/0097152 A1 · Medical device with multi-layer coating incorporating cationic steroidal antimicrobials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097152 A1
- Document ID: US20260097152A1
- Status: Published application
- Kind: A1
- Application number: 18/906,723
- Filed: 2024-10-04
- Published: 2026-04-09
- Earliest claimed: 2024-10-04
- Assignees: Brigham Young University
- Inventors: Paul B. Savage
- Web page: https://patentgrep.com/patent/US20260097152A1

## CPC

- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 27/34: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 29/085: {Macromolecular materials}
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2420/08: Coatings comprising two or more layers
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Disclosed is a multi-layered coating for application to an implantable medical device. The multi-layered coating comprises (i) a CSA coating layer comprising a polymer in which one or more CSA compounds are distributed, and (ii) a top coating layer disposed over the CSA coating layer, the top coating layer being free of CSA compounds. In use, the multi-layered coating is applied to a base substrate forming at least a portion of the implantable medical device. When the implantable medical device is exposed to a physiological environment, the top coating layer provides (i) more sustained elution of the one or more CSA compounds, as compared to the implantable medical device without the top coating layer, and/or (ii) reduced swelling of the CSA coating layer, as compared to the implantable medical device without the top coating layer.

## Claims

### Claim 1

An implantable medical device configured to elute one or more cationic steroidal antimicrobial (CSA) compounds, comprising:
a base substrate forming at least a portion of the implantable medical device;
a multi-layered coating disposed on the base substrate, the multi-layered coating comprising
(i) a CSA coating layer disposed over the base substrate, the CSA coating layer comprising a polymer in which one or more CSA compounds are distributed, and
(ii) a top coating layer disposed over the CSA coating layer, the top coating layer being free of CSA compounds,
wherein when the implantable medical device is exposed to a physiological environment, the top coating layer provides
(i) more sustained elution of the one or more CSA compounds, as compared to the implantable medical device without the top coating layer, and/or
(ii) reduced swelling of the CSA coating layer, as compared to the implantable medical device without the top coating layer.

### Claim 2 (depends on 1)

The implantable medical device of claim 1, wherein the implantable medical device comprises a catheter.

### Claim 3 (depends on 2)

The implantable medical device of claim 2, wherein the catheter is a peripherally inserted central catheter (PICC).

### Claim 4 (depends on 1)

The implantable medical device of claim 1, wherein the one or more CSA compounds comprise a CSA compound that includes cationic groups linked to a sterol backbone with non-hydrolysable linkages.

### Claim 5 (depends on 4)

The implantable medical device of claim 4, wherein the non-hydrolysable linkages are ether linkages.

### Claim 6 (depends on 5)

The implantable medical device of claim 5, wherein the one or more CSA compounds comprise CSA-131.

### Claim 7 (depends on 1)

The implantable medical device of claim 1, wherein the one or more CSA compounds comprise a CSA compound in the form of a sulfonic acid addition salt.

### Claim 8 (depends on 7)

The implantable medical device of claim 7, wherein the sulfonic acid addition salt is a naphthalenedisulfonic acid (NDSA) salt.

### Claim 9 (depends on 8)

The implantable medical device of claim 8, wherein the NDSA salt is a 1,5-NDSA salt.

### Claim 10 (depends on 1)

The implantable medical device of claim 1, wherein the CSA coating layer, the top coating layer, or both comprise a polyurethane, silicone elastomer, polyethylene glycol (PEG), polyvinyl alcohol (PVA), fluoropolymer (e.g., polytetrafluoroethylene), polyvinylpyrrolidone (PVP), polysulfone (PSU), or combination thereof.

### Claim 11 (depends on 1)

The implantable medical device of claim 1, wherein the CSA coating layer is formed from a CSA coating composition that includes the one or more CSA compounds at a concentration of 10% (w/w) to 60% (w/w), based on weight of total solids of the CSA coating composition.

### Claim 12 (depends on 1)

The implantable medical device of claim 1, wherein the multi-layered coating further comprises a primer layer disposed between the CSA coating layer and the base substrate.

### Claim 13 (depends on 12)

The implantable medical device of claim 12, wherein the primer layer comprises silicone.

### Claim 14 (depends on 1)

The implantable medical device of claim 1, wherein a ratio of thickness of the CSA coating layer to thickness of the top coating layer is 0.75 to 3.

### Claim 15

A method of manufacturing an implantable medical device configured to elute one or more cationic steroidal antimicrobial (CSA) compounds, comprising:
applying a CSA coating layer over a base substrate, the base substrate forming at least a portion of the implantable medical device, the CSA coating layer comprising a polymer in which one or more CSA compounds are distributed; and
applying a top coating layer over the CSA coating layer, the top coating layer being free of CSA compounds,
wherein when the implantable medical device is exposed to a physiological environment, the top coating layer provides
(i) more sustained elution of the one or more CSA compounds, as compared to the implantable medical device without the top coating layer, and/or
(ii) reduced swelling of the CSA coating layer, as compared to the implantable medical device without the top coating layer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the CSA coating layer, the top coating layer, or both are applied via dip coating, spray coating, spin coating, electrospinning, electrophoretic deposition (EPD), solvent casting, thermal spraying, or combination thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the multi-layer coating provides multiple weeks of at least a 50% reduction in planktonic and/or biofilm microbial growth on the implantable medical device, when exposed to a physiological environment, as compared to the implantable medical device without a CSA coating layer.

### Claim 18 (depends on 15)

The method of claim 15, wherein the implantable medical device comprises a peripherally inserted central catheter (PICC).

### Claim 19 (depends on 15)

The method of claim 15, wherein the one or more CSA compounds comprise a CSA compound that includes cationic groups linked to a sterol backbone with non-hydrolysable linkages.

### Claim 20 (depends on 15)

The method of claim 15, wherein the one or more CSA compounds comprise a CSA compound in the form of a naphthalenedisulfonic acid (NDSA) salt.
